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Abstract  
Background:  Enterococci  are  used  in  a  large  number  of  dairy  products,  such  as  starter 
cultures in food supplements and in foods considered functional. In vitro gut fermentation 
models  present  an  unmatched  opportunity  of  performing  studies  frequently  allenged  in 
humans and animals owing to ethical concerns. A dynamic model of the human intestinal 
microbial  ecosystem  (SHIME)  was  designed  to  better  simulate  conditions  intestinal 
microbiota. 
 
Methods: The SHIME model was used to study the effect of Enterococuus faecium CRL 183 
on the fermentation pattern of the colon microbiota. Initially, an inoculum prepared from 
human feces was introduced into the reactor vessels and stabilized over 2 wk using a culture 
medium. This stabilization period was followed by a 2-wk control period during which the 
microbiota were monitored. The microbiota were then subjected to a 4-wk treatment period 
by adding 10
8 CFU/mL of the Enterococcus faecium CRL 183 to vessel one (the stomach 
compartment). 
 
Results:  The  addition  resulted  into  an  overall  increase  of  bacterial  marker  populations 
(Enterobacteriaceae, Lactobacillus spp., Bifidobacterium spp. and Clostridium spp.), with a 
significant increase of the Lactobacillus ssp. and Bifidobacterium ssp populations. The short-
chain fatty acid (SCFA) concentration increased during the supplementation period; this was 
due  mainly  to  a  significant  increase  in  the  levels  of  acetic,  butyric  and  propionic  acids. 
Ammonium concentrations increased during the supplementation period.  
 
Conclusions: Results showed that the major effect of E. faecium CRL 183 was found in the 
ascendant and transverse colon. 
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BACKGROUND: 
The gastrointestinal (GI) tract is colonized by a vast community of symbionts and 
commensals that harbor a complex and diverse ecology of microorganisms comprised of 400-
500 species with levels reaching 10
14 CFU/g of intestinal contents in the large intestine [1]. 
These microbes have far-reaching implications on health in that they affect immunity and 
digestion of nutrients. Microbial interactions contribute to the homeostasis of the gut bacterial 
microbiota  and  destabilization  of  this  microorganism  ecosystem  results  in  various  GI 
disorders [2]. It has been suggested that probiotics help to maintain the GI equilibrium of the 
indigenous  microbiota  and  benefit  the  host’s  health.  They  are  thus  defined  as  “live 
microorganisms, that when administered in an adequate amounts, confer a health benefit on 
the host” [3]. Probiotic strains are considered as safe and non-pathogenic [4].  
Enterococci are used in a large number of dairy products, such as starter cultures in 
food supplements and in foods considered functional [5]. Currently, many researchers seek 
microorganisms that have probiotic properties, as is the case of, for example, Enterococcus 
faecium CRL 183. Our research group verified that E. faecium CRL 183 has the capacity to 
survive in and colonize the gastrointestinal tract of rats [6], one of the prerequisites for being 
considered probiotic [7], since the viability  of lactic bacteria  can be lost  on exposure to 
gastric  acid  and  to  bile  salts  [8].  Our  group  also  observed  that  the  consumption  of  200 
mL/day of soymilk fermented with E. faecium CRL 183 and Lactobacillus helveticus subsp. 
jugurti 416 by normocholesterolemic adult men, for a period of 6 weeks, reduced the levels 
of total cholesterol and of the LDL fraction and led to an increase of about 10% in HDL-C 
levels [9]. Others beneficial health effects, such as partial inhibition of breast cancer [10], 
prevention  of  cancer  colon  [11]  and  osteoporosis  [12]  have  also  been  achieved  with  E. 
faecium CRL 183. 
However,  the  influence  of  E.  faecium  consumption  on  human  gut  microbial 
fermentation has been little investigated to date. For that reason, the aim of our study was to 
investigate the effects of E. faecium CRL 183 on the fermentative capacity of the simulated 
microbiota of the colon.  
 
METHODS: 
Preparation of the E. faecium CRL 183 cells:  
At weekly intervals, a pure culture of E. faecium CRL 183 was inoculated  into MRS 
Agar culture medium (Acumedia, Baltimore). The bacteria in the log phase was centrifuged 
(4000 x g, 10min., 4ºC) and washed with sterile peptone water. The E. faecium cells were 
kept at the concentration of 10
8 CFU/mL in sterile peptone water until use [6]. 
 
Long-term SHIME run: 
The SHIME is a simulator of the human intestinal microbial ecosystem [13,14] in 
which the environmental conditions (pH, residence time, inoculum, and  temperature) are 
controlled  to  resemble  those  of  in  vivo  experiments.  A  SHIME  system  consists  of  five 
double-jacketed  vessels,  respectively  simulating  the  stomach,  the  small  intestine,  and  the 
ascending, transverse and descending colon, with a total retention time of 72 h (Figure 1). Functional Foods in Health and Disease 2011; 10:389-402                             Page 391 of 402 
Reactor setup and the composition of the liquid feed (Table 1), which entered the system 3 
times per day were previously described by Possemiers et al. [15].  
 
 
 
Figure  1.  Schematic  representation  of  the  Simulator  of  the  Human  Intestinal  Microbial 
Ecosystem (SHIME) 
 
The three colon vessels of the SHIME reactor were inoculated with bacteria from a 
fecal sample of a healthy 22-year-old adult female volunteer with no history of antibiotic 
treatment 6 months prior to the study. Aliquots (10 g) of freshly fecal samples were diluted 
and homogenized with 100 mL sterilized phosphate buffer (0.1 mol/L, pH 7), containing 1 
g/L sodium  thioglycolate as  reducing agent.  After removal of the particulate material  by 
centrifugation, the supernatants were pooled and 50 mL was introduced into each of the colon 
simulation vessels.  
 
Table 1. Ingredients (g) for one liter of the basal feed utilized in Shime reactor 
 
Ingredient  Quantity necessary for 1L 
Arabinogalactan  1.0 
Pectin  2.0 
Xilan  1.0 
Potato starch  3.0 
Glucose  0.4 
Yeast extract  3.0 
Peptone  1.0 
Mucin  4.0 
Cystein 
Sterile distilled water  
0.5 
1000 
 
The microbial inoculum was stabilized over a period of 2 weeks on a carbohydrate-
based  medium  and  allowed  to  adapt  to  the  specific  environmental  conditions  of  the 
ascending,  transverse  and  descending  colon  in  terms  of  pH  range,  retention  time  and 
available carbon sources [15]. An initial stabilization period of two weeks after inoculation 
was applied to allow the intestinal bacteria to adapt to the environmental conditions present in 
the colon vessels and to form a stable microbial community representative of the one present 
in the gastrointestinal tract [20]. Upon stabilization, the SHIME run included 2 weeks of 
basal period (to quantify all steady-state bacterial parameters which were used as starting 
point to evaluate the effect of a specific treatment), 4 weeks of treatment period in which Functional Foods in Health and Disease 2011; 10:389-402                             Page 392 of 402 
3mL of 10
8 CFU/mL of E. faecium CRL 183  were added once per day to the stomach 
compartment. Finally, a 2-week washout period without E. faecium addition. 
 
Microbiological analysis 
At weekly intervals, throughout the entire experimental period, (basal, treatment and 
washout), 5 mL- samples were collected from the reactors for microbiological examinations. 
Analysis of the composition of the intestinal microbiota was based on the enumeration of 
total aerobic and anaerobic bacteria, Enterococcus ssp., Lactobacillus ssp., Bifidobacterium 
ssp., Enterobacteria and, Clostridium ssp. One mL of a sample taken from each reactor was 
suspended into 99 mL  peptone water. Serial  dilutions  were prepared and inoculated into 
selective  culture  media:  total  aerobic  and  anaerobic  counts:  -  Standard    Methods  Agar 
(Acumedia,  USA; 37ºC/48h);  Enterococcus  spp.: - KF Streptococcus Agar (Acumedia, 
USA; 37ºC/48h) [16]; Lactobacillus  spp.:- MRS Agar (Merck, Germany;  37ºC/48h, under 
anaerobiosis); Bifidobacterium spp.:- Bifidobacterium formulated medium BIM-25 (supplier, 
37ºC/72h,  under  anaerobiosis)  [17],  Enterobacteria:-  MacConkey  Agar  (Acumedia,  USA; 
37ºC/48h) and Clostridium spp.: RCA Agar (Difco, France; 37ºC/48h, under anaerobiosis) 
[18]. 
 
Analysis of short-chain fatty acid and ammonium  
Once  a  week,  throughout  the  entire  experimental  period  (basal,  treatment  and 
washout), samples were collected from the reactors for analysis of short-chain fatty acids 
(SCFA) and ammonium. The analysis was carried in triplicate.  
Every  week,  the  levels  of  short-chain  fatty  acids  (SCFA)  were  determined  from 
samples collected from the reactors and frozen to  -20ºC. The SCFA were extracted with 
diethyl ether and determined using a gas chromatograph equipped with a flame-ionization gas 
detector, a capillary split/splitless injector and an HP-INNOWAX column with a 30 m x 0.25 
mm x 0.25 m inlet (Shimadzu GC2010), using hydrogen as carrier gas at a flow rate of 1.56 
mL/min. The temperatures of the column, injector and detector were 170, 250 and 280 ºC, 
respectively [19, 20]. 
The  ammonia  content  was  determined  using  a  selective  ion  meter  (710A  model, 
Orion)  coupled  to  an  ammonia  selective-ion  electrode  (Orion  95-12).  The  apparatus  was 
calibrated using 0.1M standard ammonium chloride solutions, at the concentrations of 10, 
100 and 1000 mg/L ammonia. Each 25 mL of sample was added with 0.5 mL ISA solution (a 
pH-adjusting Ionic Strength Adjuster (Orion) – a pH-adjusting and an ionic force solution). 
All measurements were taken at 25°C [21]. 
 
Statistical analysis 
Significance of all results was investigated using the statistical software Sigma Stat 
5.0.  with one-way ANOVA, and individual means were compared using the Tukey's test. 
 
RESULTS AND DISCUSSION: 
Microbiological evaluation 
It is estimated that the gastrointestinal microbiota harbors around 10
14 bacteria. This 
microbiota undergoes both qualitative and quantitative changes depending on the locale of 
colonization.  The  huge  complexity  of  this  microbiota,  which  are  often  unculturable 
microorganisms (30 to 70%) in culture media, in addition to being located in difficult-to-
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access areas of the digestive tract, which would require invasive methods to collect them, are 
the limiting factors for a more precise analysis [22].  
An  investigative  alternative  is  the  use  of  continuous  or  semi-continuous  models 
simulating the large intestine. The continuous models was validated based on the intestinal 
contents of sudden death victims [23]. Among the advantages of this model are the ease-of-
use, the possibility to use radioactive substances and the low cost [24].  
Table 2 shows the microbiological counts of the flasks that simulated the ascendant, 
transverse and descendant colon of the SHIME reactor. Using selective growth media, the 
microbiological analyses revealed the influence of the administration of E. faecium CRL 183 
on the composition of the intestinal microbial community. 
With regard to the enterobacterial population, no quantitative change was observed 
during the treatment period. However, Bedani et al., [25] observed a significant increase in 
the numbers of these microorganisms in the feces of rats that had consumed pure cells of E. 
faecium CRL 183 during 30 days. 
 
Table 2.  Average plate count measurements (±SEM), expressed in log CFU/ mL, for the 
different microbial groups, SHIME compartments and periods 
 
Bacterial groups  Colon 
ascendans 
Colon 
transversum 
Colon 
descendans 
Basal       
Enterococcus spp.  6.62
A ± 0.47  7.37
A ± 0.05  8.27
A ±  0.03 
Enterobacteria  7.30
A ± 0.14  6.23
 A ±0.08  6.53 
A±0.08 
Lactobacillus spp.  6.95
 A ± 0.05  4.13
A ± 0.22  7.68
A ± 0.09 
Bifidobacterium spp.  6.88
A ± 0.05  6.08
 A ± 0.12  9.25
A ± 0.03 
Clostridium spp.  7.72 
A± 0.01  7.80
 A ± 0.01  7.72
A ± 0.02 
Total aerobes  7.63
A± 0.04  7.16
A± 0.01  7.66
A± 0.01 
Anaerobes facultative  6.68
 A ± 0.10  7.22
 A ± 0.07  7.68
 A ± 0.0 
Treatment       
Enterococcus spp.  8.90 
B ± 0.77  9.06 
B ± 0.54  8.72 
A ± 0.54 
Enterobacteria  7.00
 A ± 0.27  7.11
 A ± 0.83  6.96 
A ± 0.93 
Lactobacillus spp.  8.54
 B ± 1.54  8.25 
B ± 1.64  8.50 
A ± 0.54 
Bifidobacterium spp.  9.40
B ± 0.82  8.74
 B ± 0.94  9.50 
A ± 0.66 
Clostridium spp.  8.88
 A ± 1.33  8.59
 A ± 1.52  8.71
 A ± 1.43 
Total aerobes  8.45
 A ± 1.80  8.58
 A ± 1.04  8.22
 A ± 0.07 
Anaerobes facultative  8.82
 B ± 0.53  8.90
 B ± 0.56  8.85
 B ± 0.56 
Washout       
Enterococcus spp.  7.46
 AB ± 0.22  7.01 
A ± 0.64  7.24 
B ± 0.31 
Enterobacteria  5.37
 B ± 0.07  5.79
 A ± 0.51  5.66 
B ± 0.25 
Lactobacillus spp.  7.28
 B ± 0.02  7.13 
B ± 0.02  7.08
 A ± 0.01 
Bifidobacterium spp.  7.99
A ± 0.06  7.88
 CB ± 0.89  8.00 
B ± 0.09 
Clostridium spp.  7.79
 A ± 0.45  7.54
A ± 0.62  7.56
 A ± 0.50 
Total aerobes  7.86
 A ± 0.06  7.85
A± 0.14  7.71
 A ± 0.08 
Anaerobes facultative  8.08
 AB ± 0.53  8.05
 AB ± 0.03  7.97
 AC ± 0.02 
 
Different letters indicate significantly different results (P<0.05) in same microbial group and same 
compartment (colon ascendans, transversum or descendans). Functional Foods in Health and Disease 2011; 10:389-402                             Page 394 of 402 
In previous studies conducted by our research group [26], no quantitative change was 
observed in the microbiota of Enterococcus spp contained in the feces of rats that had been 
daily fed with E. faecium CRL 183 during 30 days. However, in the SHIME reactor, during 
the  treatment  period,  a  statistically  significant  increase  in  the  Enterococcus  ssp  counts 
occurred in the ascendant (1 log cycle) and transverse (2 log cycles) colons. Probably, E. 
faecium  CRL  183  has  a  greater  capacity  to  colonize  and  adhere  to  the  ascending  and 
transversal regions of the colon. According to Jin et al [27], E. faecium occupies binding sites 
in the mucosal cells of the ascendant colon, which allow their adherence. 
The concentration of the Lactobacillus ssp population increased significantly by two 
logarithmic cycles in the ascendant colon and by three log cycles in the transverse colon 
during  the  treatment  phase.  However,  in  the  descendant  colon,  there  was  no  statistically 
significant alteration during the same phase. According to Marteau [28], the colon is the 
primary microbial colonization site, a region consisting of different niches and ecosystems. 
The  pH  in  the  ascending  colon  is  about  5.6  to  5.9,  a  value  that  favors  the  growth  of 
Lactobacillus ssp. According to Coudeyras and Forestier [29], the ascendant and transverse 
regions of the colon harbor a microbiota that is very similar to that of the stomach, with 
predominance of facultative aerobes and anaerobes. The dominant genus in this region is 
Streptococcus ssp, but Lactobacillus ssp. and Enterococcus ssp also being found here, both of 
which are species that are generally present in the intestinal lumen contents. The results show 
that  the  administration  of  E.  faecium  stimulated  the  growth  of  Lactobacillus  ssp  in  the 
ascendant and transverse colons.  
In the descendant colon, the population of bifidobacteria accounts for about 3 to 5% 
of the total microbiota in this region [29]. Over the basal period, a higher count was observed 
(10
8 CFU/mL) in the descending colon, as compared to the ascendant and transverse regions 
(10
5  UFC/mL).  However,  the  treatment  with  E.  faecium  stimulated  the  growth  of  the 
population of bifidobacteria only in the ascending and transverse colon regions. Bedani et al., 
[25] observed that the animals that received a suspension of a pure E. faecium CRL 183 
culture presented an increase in the fecal bifidobacteria population in the feces. 
As  for  the  population  of  Clostridium  spp.,  there  was  no  statistical  significant 
difference during the treatment period in the three regions of the colon evaluated. Bacteria 
belonging to this genus may be harmful due to their metabolic activity and the pathogenic 
character  of  some  species  [30].  The  species  belonging  to  the  Clostridium  genus  may  be 
involved  in  inflammatory  processes  of  intestinal  diseases  [31].  Bedani  et  al,  [25]  also 
observed that there was no alteration in the fecal population of Clostridium ssp in rats that 
consumed cultures of E. faecium CRL 183. 
  With  regard  to  total  aerobes,  there  was  no  statistically  significant  change    in  the 
population  of  these  microorganisms  during  the  treatment  period.  As  for  the  facultative 
aerobes, a significant increase was noted in the ascendant, transverse and descendant colons. 
According  to  Coudeyras  and  Forestier  [29],  one  of  the  main  differences  between  the 
microbiota found in the feces and that in the colon is related to the facultative anaerobes, 
which are abundant in the colon and practically absent from the feces. 
A comparison between the basal, treatment and washout periods allows to state that, 
in a general manner, all the microbial groups evaluated had their concentrations reduced in 
the  post-treatment  period.  According  to  Doré  and  Corthier  [32],  the  dominant  intestinal 
microbiota is resistant to modifications. The administrations of probiotics or prebiotics may 
temporarily change intestinal homeostasis. Furthermore, it may be stated that E. faecium CRL Functional Foods in Health and Disease 2011; 10:389-402                             Page 395 of 402 
183  stimulate  the  growth  of  some  microbial  groups,  such  as;  Lactobacillus  ssp.,  and 
Bifidobacterium  ssp  in  the  ascendant  and  transverse  regions  of  the  colon,  exerting  little 
influence in the descending region.  
 
Ammonium concentration 
The  intestinal  microbiota  is  a  complex  ecosystem  composed  of  interdependent 
bacteria. Certain bacteria stabilize themselves solely as a function of metabolites produced by 
other bacteria, and together they transform complex polymers into simple molecules [29].  
The final  metabolites from  the digestion of  glycides by the intestinal  bacteria  are 
short-chain fatty acids, H2 and CO2. On the other hand, the degradation products of proteins 
are short-chain  fatty acids,  branched fatty  acids, phenolic derivatives, indolic derivatives, 
polyamines  and  ammonia.  The  deleterious  metabolites  are  amines  and  ammonia.  These 
metabolites may be either absorbed by the body or excreted through urine [28]. Studies have 
demonstrated  that  high  concentrations  of  ammonia  act  as  tumor-promoting  agents  in  the 
colon, since they are toxic to the epithelial cells of the intestine [22]. 
 
Figure  2  shows  the  concentration  of  ammonium  ion  in  the  basal,  treatment  and 
washout phases. 
 
   
 
Figure 2. Average ammonium ion production (ppm) in shime run, during basal, treatment 
and washout period. Statistically significant differences among the samples were investigated 
with one-way ANOVA (samples with the same letter on the top of the bar are not statistically 
different, P<0.05). 
 
During  the  treatment  period  with  E.  faecium,  the  concentration  values  of 
concentration of ammonium ion increased significantly in all the regions investigated (Figure 
2). Similar results were observed by Bedani et al [21], who noted a significant increase in the 
concentration of ammonia in that had been fed daily doses of E. faecium CRL 183 cells. 
Pomessier et al., [15] and Payne et al., [33] also observed an increase in the ammonia content 
in an experiment utilizing a dynamic simulator of the human microbial ecosystem. 
Urease is expressed by many bacteria and mediated by the hydrolysis of urea into 
ammonia, which serves a source of bacterial nitrogen. According to Laukoová and Kuncová 
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[34], some strains of E. faecium have urease activity, which would explain the increase in the 
concentration of ammonia during the administration of E. faecium cells. 
 
Fermentation capacity 
One of the most important factors for the persistence of the intestinal microbiota is the diet, 
which does not only provides the host with nutrients, but also the intestinal microorganisms 
[18]. In this sense, the carbohydrates that are not digested in the colon are metabolized by 
microorganisms into SCFA, particularly acetate, butyrate and propionate. The formation of 
short-chain fatty acids is of great importance, since they are sources of energy and serve as 
microbial substrate, in addition to being related to several organic, local and systemic effects 
[35]. The production of SCFA depends on the substrates available and the microorganisms 
present in the gastrointestinal tract [36]. 
Figure 3 depicts the production of acetate during the periods of basal, treatment and 
washout  in  the  Shime  vessels.  During  treatment  with  E.  faecium,  a  significant  increase 
occurred  in  the  production  of  acetate  in  all  the  reactors  analyzed,  however,  the  greatest 
concentration of this acid occurred in vessel one, which simulates the ascending region of the 
colon. In the washout period, the levels of acetate diminish, however, only in the transverse 
colon these levels differ statistically from the basal period.  
A significant increase in the concentration of butyrate was observed in the vessels 
simulating  the  transverse  and  descendant  colon  (Figure  4).  Butyrate  is  considered  the 
preferred fuel of the epithelial cells of the colon, which derive 70% of their energy from the 
oxidation  of  this  substrate.  Butyrate  also  reduces  the  expression  of  proinflammatory 
cytokines  of    tumor  necrosis  factor-α  (TNF-α),  TNF-β,  interleukine-6  (IL-6)  and  IL-1β 
through activation of  the nuclear growth inhibiting factor kB (NF-kB) (23). In addition, it 
has been proposed that butyrate reduces the risk of colon cancer due to is ability to inhibit the 
genotoxic capacity of nitrosamines and of hydrogen peroxide, as well as to induce different 
levels  of  apoptosis,  differentiation  and  cessation  of  the  cellular  cycle  of  colon  cancer  in 
animal models [36]. 
 
 
 
Figura 3. Average SFCA production (acetate) during the SHIME run, in the basal, treatment 
and  washout period, respectively.  Statistically  significant  differences  among  the  samples  were 
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investigated  with  one-way  ANOVA  (samples  with the  same  letter  on the  top  of  the  bar  are  not 
statistically different, P<0.05) 
 
 
 
Figura  4.  Average  SFCA  production  (butyrate)  during  the  SHIME  run,  in  the  basal, 
treatment and washout period, respectively. Statistically significant differences among the 
samples were investigated with one-way ANOVA (samples with the same letter on the top of 
the bar are not statistically different, P<0.05) 
 
 
 
 
Figure  5.    Average  SFCA  production  (propionate)  during  the  SHIME  run,  in  the  basal, 
treatment and washout period, respectively. Statistically significant differences among the 
samples were investigated with one-way ANOVA (samples with the same letter on the top of 
the bar are not statistically different, P<0.05) 
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Butyrate has been studied in clinical applications, particularly inflammatory bowel 
diseases of the colon. While available data are not entirely conclusive, this substance appears 
to  have  a  useful  therapeutic  role  complementary  to  that  of  standard  drugs.  A  body  of 
experimental data also suggests that this short-chain fatty acid may exert preventive action 
against colorectal cancer, but for the moment this is still a hypothesis that remains to be 
verified. More generally, butyrate has been shown to be useful in certain types of diarrhea, 
particularly chronic forms, by promoting absorption of water and electrolytes [37]. 
Previous  studies  conducted  using  an  animal  model  allowed  to  observe    that  the 
consumption of pure cells of E. faecium CRL 183 inhibited the development of colon cancer 
[11]. Within this context, one may assume that this inhibition may be connected with the 
production of butyrate observed in in vitro experiments. 
With regard to propionate, a significant increase was observed in the concentrations in 
the vessels 2 and 3, that simulate the transverse and descendant colon during the treatment 
with E. faecium. In the washout period, a reduction in the concentration of this acid was 
found to have occurred, however only in the descendant colon this variation was statistically 
significant (Figure 5). 
 
 
 
Figure  6.  Average  SFCA  production  during  the  SHIME  run  in  the  treatment  period. 
Statistically  significant  differences  among  the  samples  were  investigated  with  one-way 
ANOVA (samples with the same letter on the top of the bar are not statistically different, 
P<0.05) 
 
Figure 6 refers to the production of SCFA (acetate, propionate and butyrate) during 
the treatment phase in the reactors that simulate the ascendant, transverse and descendant 
colon. The acid with the greatest production was acetate. Comparing the three compartments 
of the colon, it is observed that there was a significant difference between the ascendant colon 
and the transverse and descending colons for this acid. As for the other acids investigated 
(butyrate and propionate) there were no significant differences in the concentrations between 
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the regions of the colon. The same pattern was observed in the washout period, that is, upon 
cessation  of  the  treatment  with  E.  faecium,  the  production  of  SCFA  diminished,  but  the 
tendency between the regions of the colon remained unchanged (Figure 7). Similar results 
were observed by Van de Wiele et al., [19] in experiments using the Shime reactor.  
 
 
 
Figura  7.  Average  SFCA  production  during  the  SHIME  run  in  the  washout  period. 
Statistically  significant  differences  among  the  samples  were  investigated  with  one-way 
ANOVA (samples with the same letter on the top of the bar are not statistically different, 
P<0.05) 
 
The production of SCFA in the treatment period may be explained by the increase in 
the concentration of lactobacilli and bifidobacteria observed over the same period of time 
(Table  2),  which use the  breakdown of the starch present  in  the basal  medium  with  the 
consequent production of SCFA. According to Van de Wiele et al., [20] the increase in the 
synthesis of fatty acids creates a more acid intestinal environment, which is important for the 
colonization resistance against potentially pathogenic microorganisms. On the other hand, the 
SCFA are important sources for the colonocytes, in addition to stimulating the absorption of 
water and sodium and modulating intestinal motility [38]. 
This  study  indicates  that  the  consumption  of  E.  faecium  may  influence  the  gut 
microbiota  in  a  beneficial  way.  The  concentration  of  SCFA  increased,  whereas  a 
concentration of the harmful putrefactive metabolite (NH3) was also augmented. Apparently, 
E. faecium had greater influence on the gut microbiota of the ascendant and transversal colon. 
Limitations associated with in vitro systems [39] also should trigger further research to study 
the beneficial effects of E. faecium consumption in vivo. 
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